Holen Sie sich die Stockscreener-App
313.41
1.20%
-3.82
Handel nachbörslich:
313.10
-0.31
-0.10%
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
siRNA Therapeutics Market Poised for Rapid Growth to US$ 12.38 - openPR.com
Why Alnylam Pharmaceuticals Stock Was Soaring on Monday - AOL.com
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Atika Capital Management LLC - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Lifted by WINTON GROUP Ltd - MarketBeat
Legal & General Group Plc Has $404.83 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How Investors May Respond To Alnylam (ALNY) Expanding Cardiovascular RNAi Targets Through Tenaya Collaboration - simplywall.st
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
Capital Research Global Investors Boosts Holdings in Alnylam Pharmaceuticals - National Today
Alnylam to Webcast TTR Investor Webinar - Business Wire
Capital Research Global Investors Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Capital World Investors - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Raised by Capital International Inc. CA - MarketBeat
Swiss National Bank Has $171.37 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Holdings Raised by Jefferies Financial Group Inc. - MarketBeat
Alnylam Pharmaceuticals grants performance-based equity award to CEO - Investing.com Nigeria
12,658 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Fieldview Capital Management LLC - MarketBeat
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam nabs key additional indication for Amvuttra - MSN
Alnylam targets 25% revenue CAGR through 2030 amid AMVUTTRA launch momentum and pipeline expansion - MSN
Korea Investment CORP Grows Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Rhenman & Partners Asset Management AB Has $14.54 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics - simplywall.st
Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation - Yahoo Finance
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - Yahoo Finance
ALNYLAM PHARMACEUTICALS Executives Sell Shares - TradingView
Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After Recent Share Price Pullback - simplywall.st
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - bioworld.com
Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam - The Pharmaletter
Victory Capital Management Inc. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal - Pharmaceutical Technology
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - Yahoo Finance
Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Sahm
Alnylam Updates Hypertension Pipeline And AMVUTTRA Access Shape Valuation View - Sahm
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Responsive Playbooks and the ALNY Inflection - Stock Traders Daily
Tenaya To Evaluate Genetic Cardiovascular Targets For Alnylam - Citeline News & Insights
Alnylam board creates $18M incentive award to keep CEO through 2029 - The Business Journals
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - Investing News Network
Tenaya wins support from Alnylam in cardio disease pact - Endpoints News
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - marketscreener.com
Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam - marketscreener.com
Alnylam Pharmaceuticals (ALNY) Forms Partnership for Cardiovascu - GuruFocus
Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development - PR Newswire
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration - TipRanks
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - Seeking Alpha
Tenaya Therapeutics enters into research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics - marketscreener.com
Tenaya Therapeutics Enters into Research Collaboration with - GlobeNewswire
Focus Partners Advisor Solutions LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
CI Investments Inc. Buys 3,109 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Canada’s AMVUTTRA Reimbursement Tailwind Altering The Investment Case For Alnylam Pharmaceuticals (ALNY)? - Yahoo Finance
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Sells 6,799 Shares of Stock - MarketBeat
Alnylam CEO Greenstreet sells $2.23 million in stock - Investing.com India
Jeffrey Poulton Sells 2,206 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Pushkal Garg Sells 1,717 Shares - MarketBeat
Alnylam (NASDAQ: ALNY) EVP receives new options and RSUs - Stock Titan
Alnylam Grants CEO New Performance-Based Equity Award - TipRanks
Alnylam Reimbursement Win And Trial Progress Versus Current Valuation Signals - Yahoo Finance
Alnylam Pharmaceuticals grants performance-based equity award to CEO By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Presents a Growth Story at a Technical Turning Point - ChartMill
Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors - BioSpace
Pushkal Garg (ALNY) reports sale of 4,627 shares for $1.53M - Stock Titan
1.19%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):